Wang Linjuan, Qiu Shaowei
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Tianjin Institutes of Health Science, Tianjin, China.
Blood Sci. 2025 Aug 5;7(3):e00247. doi: 10.1097/BS9.0000000000000247. eCollection 2025 Sep.
Chimeric antigen receptor (CAR) T-cell therapy is an epoch-making immunotherapy for the treatment of relapsed or refractory (r/r) blood tumors, as demonstrated by its successful implementation in r/r B cell-derived malignancies. However, replicating this success in T-cell leukemia or lymphoma remains challenging. Among the various potential target antigens, CD7 has garnered attention as a promising candidate. CD7 CAR-T therapy is one of the most extensively studied approaches for treating r/r T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) and r/r acute myeloid leukemia (AML). Based on the source of T cells, CAR-T products can be categorized as autologous and allogeneic, both of which are being tested in clinical trials, each offering specific advantages. Allogeneic CD7 CAR-T cells outperform autologous cells in terms of reducing manufacturing costs, ensuring consistent quality, and improving affordability and availability. Despite these advantages, challenges like graft-versus-host disease (GVHD), host-versus-graft reaction (HVGR), and fratricide pose significant barriers to the clinical application of allogeneic CD7 CAR-T cells. However, innovative gene-editing techniques, such as CRISPR/Cas9 and base editing, and more promising cell sources, such as natural killer T (NKT) cells and induced pluripotent stem cells (iPSCs), are emerging as potential solutions. In this review, we discuss the different categories of CD7 CAR-T products, their application in clinical settings, and directions for refinement.
嵌合抗原受体（CAR）T细胞疗法是一种用于治疗复发或难治性（r/r）血液肿瘤的具有划时代意义的免疫疗法，其在r/r B细胞来源的恶性肿瘤中的成功应用已得到证实。然而，在T细胞白血病或淋巴瘤中复制这一成功仍然具有挑战性。在各种潜在的靶抗原中，CD7作为一个有前景的候选者受到了关注。CD7 CAR-T疗法是治疗r/r T细胞急性淋巴细胞白血病/淋巴细胞淋巴瘤（T-ALL/LBL）和r/r急性髓细胞白血病（AML）研究最广泛的方法之一。根据T细胞的来源，CAR-T产品可分为自体和异体两种，这两种产品都在临床试验中进行测试，各自具有特定的优势。异体CD7 CAR-T细胞在降低制造成本、确保质量一致性以及提高可负担性和可及性方面优于自体细胞。尽管有这些优势，但移植物抗宿主病（GVHD）、宿主抗移植物反应（HVGR）和自相残杀等挑战对异体CD7 CAR-T细胞的临床应用构成了重大障碍。然而，诸如CRISPR/Cas9和碱基编辑等创新基因编辑技术，以及诸如自然杀伤T（NKT）细胞和诱导多能干细胞（iPSC）等更有前景的细胞来源正在成为潜在的解决方案。在这篇综述中，我们讨论了CD7 CAR-T产品的不同类别、它们在临床环境中的应用以及改进方向。
